Loading…
Loading…
PSTV (Plus Therapeutics, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
PSTV does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for PSTV and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for PSTV and 80,000+ other tickers.
See exactly how PSTV's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for PSTV and 80,000+ other tickers.
Plus Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, dedicated to the development, manufacturing, and market introduction of therapeutic solutions for cancer patients and individuals with other serious illnesses. A cornerstone of their pipeline is Rhenium-186 NanoLiposome (R-186 NL), a patented radiotherapy specifically engineered to address difficult central nervous system (CNS) cancers, such as recurrent glioblastoma, leptomeningeal metastases, and various brain cancers affecting children. The company has also secured a licensing agreement with NanoTx, Corp. to…
Cerenome highlights SNO/ASCO data showing REYOBIQ CSF distribution and safety, and CNSide's potential to reduce monthly LM treatment costs by up to 47%.
HOUSTON, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence, today announced financial results for the second quarter ended June 30, 2026, and provided an overview of recent and upcoming business highlights.
HOUSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has signed an in-network provider agreement with Health Care Service Corporation (“HCSC”), effective August 1, 2026, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. HCSC represents approximately 27.3 million commercial and Medicare Advantage covered lives and operates Blue Cross and Blue Shield plans in Texas, Illinois, Montana, New Mexico, and Oklahoma and offers Medicare Advantage plans in 30 states and Washington, D.C.
Shares of Plus Therapeutics, Inc. (NASDAQ: PSTV - Get Free Report) have been given a consensus recommendation of "Hold" by the seven analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to
HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), today announces that its corporate rebrand to Cerenome will be completed as scheduled. Effective August 3, 2026, the Company's name will become Cerenome, Inc. The Company's common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol “CNSY,” effective market open on the same day.